SCHEMBL4098315

SCHEMBL4098315

CC(C)Cc1nc2nc3ccccc3nc2c(=O)n1Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
TLR7 Q9NYK1 1/20 0.47
ALOX5AP P20292 3/20 0.46
PDE4A P27815 3/20 0.45
PDE4B Q07343 3/20 0.45
PDE4C Q08493 3/20 0.45
PDE4D Q08499 3/20 0.45
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
POLB P06746 3/20 0.41
THRB P10828 1/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 2/20 0.41
RAB9A P51151 2/20 0.41
RECQL P46063 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HPGD P15428 1/20 0.41
CFTR P13569 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4752671 0.88 PDE4A (0.42) LMNAMEN1KMT2ATLR7ALOX5AP
SCHEMBL5118726 0.82 PDE4A (0.50) LMNAMEN1KMT2ATLR7PDE4A
SCHEMBL5106687 0.81 LMNA (0.50) LMNAMEN1KMT2ATLR7ALOX5AP
SCHEMBL5108726 0.78 MEN1 (0.46) LMNAMEN1KMT2ATLR7ALOX5AP
SCHEMBL13981796 0.78 CACNA2D1 (0.40) LMNAMEN1KMT2AALOX5APPDE4A
SCHEMBL4109641 0.78 ALDH1A1 (0.41) LMNAMEN1KMT2AALOX5APPDE4A
SCHEMBL14367275 0.78 PDE4A (0.69) LMNAMEN1KMT2ATLR7PDE4A
SCHEMBL4091105 0.78 PDE4A (0.51) LMNAMEN1KMT2ATLR7PDE4A
SCHEMBL5120052 0.77 CYP1A2 (0.53) LMNAMEN1KMT2ATLR7PDE4A
SCHEMBL5119264 0.76 PDE4A (0.51) LMNAMEN1KMT2ATLR7PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090214529-A9 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2009-08-27 US disclosed
US-20090214529-A9 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2009-08-27 US disclosed
US-20090214529-A9 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2009-08-27 US disclosed
WO-2008147852-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-12-04 WO disclosed
WO-2008147852-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-12-04 WO disclosed
US-20080292626-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-11-27 US disclosed
US-20080292626-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-11-27 US disclosed
US-20080292626-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090214529-A9 KINESIN INHIBITORS KIF5B, KIF5A, KIF5C LMNA 3815/4885MEN1 2194/4885KMT2A 1540/4885
US-20080292626-A1 KINESIN INHIBITORS KIF5B, KIF5A, KIF5C LMNA 3815/4885MEN1 2194/4885KMT2A 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.